Lymphangioleiomyomatosis (LAM) Registry
Primary Purpose
Lung Diseases, Lymphangiomyomatosis
Status
Completed
Phase
Locations
Study Type
Observational
Intervention
Sponsored by
About this trial
This is an observational trial for Lung Diseases
Eligibility Criteria
No eligibility criteria
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00005486
First Posted
May 25, 2000
Last Updated
February 17, 2016
Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
1. Study Identification
Unique Protocol Identification Number
NCT00005486
Brief Title
Lymphangioleiomyomatosis (LAM) Registry
Study Type
Observational
2. Study Status
Record Verification Date
December 2005
Overall Recruitment Status
Completed
Study Start Date
July 1997 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
June 2003 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
4. Oversight
5. Study Description
Brief Summary
To establish a registry of individuals with LAM by forming a consortium of six clinical centers and referring physicians who treat LAM patients.
Detailed Description
BACKGROUND:
LAM is a rare multi-system disease that can affect the lungs of young women, is of uncertain cause, is usually progressive, and can cause debilitating lung disease which may be corrected with lung transplantation. Several hundred women with the disease have been identified, largely through a LAM Foundation in Cincinnati, Ohio.
DESIGN NARRATIVE:
The Data and Coordinating Center is located at the Cleveland Clinic Foundation. The registry has six major clinical centers: Cleveland Clinic Foundation, Mayo Clinic-Rochester, National Heart, Lung, and Blood Institute, National Jewish Medical and Research Center, New England Medical Center, and Stanford University Medical Center. Data and lung tissue collected by the registry will be used to characterize the clinical features and natural history of the disease and to determine the efficacy of lung transplantation in this disorder. Eligible patients are to be seen yearly for up to 4 years at the Clinical Centers or, in some cases, by individual referring physicians. Tissue collected by the LAM Registry will be stored at a central NHLBI repository. Outcome events include measures of pulmonary function (eg, spirometry and, when available, lung volumes and diffusing capacity), arterial blood gases or oximetry, walking and resting oxygen titration, cardiopulmonary stress testing, cause-specific mortality, functional status, and clinical events associated with lung transplantation.
The Office of Research on Women's Health provided funding in FY 1997 in the amount of $100,000.
The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lung Diseases, Lymphangiomyomatosis
7. Study Design
10. Eligibility
Sex
Female
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
No eligibility criteria
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gerald Beck
Organizational Affiliation
The Cleveland Clinic
12. IPD Sharing Statement
Citations:
Citation
Sullivan EJ, Stoller JK. The registry for individuals with lymphangioleiomyomatosis. In J. Moss, editor. LAM and Other Diseases Characterized by Smooth Muscle Proliferation. Marcel Dekker, New York, NY, pp 99-110, 1998.
Results Reference
background
PubMed Identifier
9925106
Citation
Sullivan EJ, Beck GJ, Peavy HH, Fanburg BL. Lymphangioleiomyomatosis Registry. Chest. 1999 Jan;115(1):301. doi: 10.1378/chest.115.1.301. No abstract available.
Results Reference
background
PubMed Identifier
9872207
Citation
Sullivan EJ. Lymphangioleiomyomatosis: a review. Chest. 1998 Dec;114(6):1689-703. doi: 10.1378/chest.114.6.1689. No abstract available.
Results Reference
background
PubMed Identifier
16210669
Citation
Ryu JH, Moss J, Beck GJ, Lee JC, Brown KK, Chapman JT, Finlay GA, Olson EJ, Ruoss SJ, Maurer JR, Raffin TA, Peavy HH, McCarthy K, Taveira-Dasilva A, McCormack FX, Avila NA, Decastro RM, Jacobs SS, Stylianou M, Fanburg BL; NHLBI LAM Registry Group. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med. 2006 Jan 1;173(1):105-11. doi: 10.1164/rccm.200409-1298OC. Epub 2005 Oct 6.
Results Reference
background
Learn more about this trial
Lymphangioleiomyomatosis (LAM) Registry
We'll reach out to this number within 24 hrs